

ASX Announcement**DIMERIX LIMITED
RESULTS OF ENTITLEMENT OFFER**

MELBOURNE, Australia, 24 January 2018: Dimerix Limited or the “Company” (ASX: DXB), a clinical stage biotechnology company today announces results from its 1 for 2 pro-rata non-renounceable Entitlement Offer of fully paid ordinary shares in Dimerix announced on 6 December 2017, opened on 13 December 2017 and closed on 19 January 2018.

The results of the Entitlement Offer were:

	No. Shares	Amount
Entitlement Offer	46,040,880	\$5,524,906
Acceptances Received	25,467,633	\$3,056,116
Shortfall	20,573,247	\$2,468,790

The Entitlement Offer Shares will be issued on the 25th January 2018 in accordance with the timetable.

Substantial shareholders, directors and management of Dimerix subscribed to entitlements to an amount of approximately \$1.3 million of the \$3 million raised.

Kathy Harrison, Dimerix CEO “We are delighted with the size of the shareholder uptake in such a large offer, which allowed each shareholder to increase their holding by an additional 50%. The funds raised provide us with the runway to commence all planned activities previously articulated.”

The Company has also conducted a number of investor meetings across Australia and offshore over the last few months and positive discussions are continuing with respect to placement of the shortfall.



**Ian Hobson
Company Secretary
Dimerix Limited**